Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant

NCT01366612 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT01366612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01366612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant
Lead sponsor
Hackensack Meridian Health
Phase
Phase 3
Overall status
Terminated
Start date
June 16, 2010
Completion date
August 18, 2020
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, myeloid malignancies, myeloproliferative disorders